News
-
-
PRESS RELEASE
Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting
Crofelemer shows promising results in reducing total parenteral support for MVID patients, presented at NASPGHAN. Jaguar Health's investigation explores breakthrough benefits for pediatric patients with intestinal failure -
-
-
PRESS RELEASE
REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrit
Ongoing trial of crofelemer in UAE shows reduction in parenteral support for pediatric intestinal failure patients. Breakthrough in MVID and SBS-IF treatment -
-
-
PRESS RELEASE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) granted RSUs to new employees effective October 20, 2025. RSUs vest over one year. The Company focuses on developing prescription medicines from rainforest plants for gastrointestinal distress -
-